Daré Bioscience reported Q1 2026 financial results and highlighted second positive DSMB review for Ovaprene Phase 3 trial, with first product revenue from Flora Sync LF5 expected in June 2026.
Key takeaways
Second positive DSMB review of Ovaprene Phase 3 interim data on May 12, 2026, recommends continuation without modification.
Flora Sync LF5 commercial launch in June 2026, marking first direct product revenue for the company.
DARE to PLAY dispensing to commence summer 2026 via Bravado Pharmaceuticals.
Ovaprene Phase 3 enrollment expected to complete in 2026, targeting primary endpoint analysis in 2027.
DARE-HPV to advance into Phase 2 study in May 2026 with ARPA-H non-dilutive funding.
DARE to RECLAIM prescription fulfillment targeted for 2027.